Application DetailsWestern Blotting (WB). A concentration of 0.1-0.5 µg/mL is recommended for WB. Human FGF-4 (precursor) has a predicted length of 206 residues and MW of 22 kDa. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
TargetFibroblast growth factor 4 (FGF-4)
SpecificityThe specificity of this antibody has been confirmed by WB against the antigen. Human; rat; expected to react with mouse due to sequence homology
Target Host SpeciesHuman
Species ReactivityHuman, Mouse (Predicted), Rat
Immunogen DescriptionA synthetic peptide (RRLYCNVGIGFHLQ) corresponding to a region (84-97) from human FGF-4. To enhance the immunological response, this peptide was coupled to carrier protein BSA.
Purity DescriptionAffinity purified on antigen column
Reconstitution InstructionsSpin vial briefly before opening. Reconstitute in 100 µL sterile-filtered, ultrapure water to achieve an antibody concentration of 1 mg/mL. Centrifuge to remove any insoluble material.
Storage InstructionsAt least 12 months after purchase at 2-8°C (lyophilized formulations). After reconstitution, aliquot and store at -20°C for a higher stability. Avoid freeze-thaw cycles
Batch NumberPlease see item label.
Expiration Date12 months after date of receipt (unopened vial).
Alternative NamesHeparin secretory-transforming protein; HST-1; HST; Transforming protein KS3; HST; KS3; HSTF1; Heparin-binding growth factor 4; HBGF-4;
Scientific BackgroundFibroblast growth factors (FGFs) bind heparin and exhibit widespread mitogenic and neurotrophic activities in a variety of different cells including mesenchymal, neuroectodermal and endothelial cells. FGF-4 is also known as Heparin secretory-transforming protein 1 (HST-1) and is reported to have mitogenic activity.